The Manitoba IBD cohort study: A population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders
The Manitoba IBD cohort study: A population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders
复制标题
DOI：
10.1111/j.1572-0241.2008.01980.x
复制
发表时间：
2008-08-01
影响因子：
9.8
通讯作者：
Bernstein, Charles N.
中科院分区：
文献类型：
--
作者：
Walker, John R.;Ediger, Jason P.;Bernstein, Charles N.
工作基础和目标：即使焦虑和情绪障碍对健康的影响，重要的是要考虑这些疾病的人与炎症性肠病（IBD）。我们评估了焦虑和情绪障碍的患病率在人群为基础的炎症性肠病cohol.METHODS：一个结构化的诊断访谈管理的参与者在队列（N = 351），并率进行了比较，年龄，性别，和地区匹配的控制从全国调查（N = 779）。一生患病率的比较表明，恐慌，广泛性焦虑，和强迫症IBD样本中的强迫症和重度抑郁症以及社交焦虑和双相情感障碍的发病率低于美国国家样本和新西兰与匹配对照的直接比较（有三种焦虑症的数据）发现，（IBD vs对照）如下：IBD中社交焦虑障碍较低（6% vs 11%，OR 0.52，95% CI 0.32-0.85），惊恐障碍无显著差异（8.0% vs 4.7%，OR 1.59，95%CI 0.96-2.63），无惊恐的广场恐怖症无显著差异（1.1% vs 0.6%，OR 1.44，95% CI 0.37-5.55），重度抑郁症更高（27.2% vs 12.3%，OR 2.20，95% CI 1.64-2.95）。比较IBD受访者和没有终身焦虑或情绪障碍，那些有障碍的生活质量较低，发病较早的IBD症状，并有一个趋势，对早期IBD diagnosis.CONCLUSIONS：临床医生应该意识到增加的患病率，抑郁症和其他可能的焦虑症的人与IBD，因为这些疾病可能会影响治疗反应和生活质量。
BACKGROUNDG AND AIMS: ven the impact of anxiety and mood disorders on health, it is important to consider these disorders in persons with inflammatory bowel disease (IBD). We assessed the prevalence of anxiety and mood disorders in a population-based IBD cohort.METHODS: A structured diagnostic interview was administered to participants in the cohort (N = 351), and rates were compared to age-, gender-, and region-matched controls drawn from a national survey (N = 779).RESULTS: A comparison of lifetime prevalence suggests higher rates of panic, generalized anxiety, and obsessive-compulsive disorders and major depression and lower rates of social anxiety and bipolar disorders in the IBD sample than in national samples in the United States and New Zealand. Direct comparisons with matched controls (with data available for three anxiety disorders) found lifetime prevalence (IBD vs controls) as follows: social anxiety disorder lower in IBD (6% vs 11%, OR 0.52, 95% CI 0.32-0.85), panic disorder not significantly different (8.0% vs 4.7%, OR 1.59, 95% CI 0.96-2.63), agoraphobia without panic not significantly different (1.1% vs 0.6%, OR 1.44, 95% CI 0.37-5.55), and major depression higher (27.2% vs 12.3%, OR 2.20, 95% CI 1.64-2.95). Comparing IBD respondents with and without lifetime anxiety or mood disorder, those with a disorder reported lower quality of life and earlier onset of IBD symptoms and there was a trend toward earlier IBD diagnosis.CONCLUSIONS: Clinicians should be aware of the increased prevalence of depression and possibly other anxiety disorders in persons with IBD as these disorders may influence response to treatment and quality of life.